Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 02, 2005. The report details changes in directors' interests in the company's Ordinary Shares, specifically regarding transactions involving the GlaxoSmithKline Employee Trust (GSK Trust).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity transactions and does not contain financial performance data.
Material Changes
On February 01, 2005, the GSK Trust transferred Ordinary Shares to participants in three specific employee incentive plans:
- 24,840 shares transferred to participants in the SmithKline Beecham Mid Term Incentive Plan.
- 2,010 shares transferred to participants in the GlaxoSmithKline Performance Share Plan.
- 1,620 shares transferred to participants in the SmithKline Beecham Employee Share Option Plan 1991.
These transactions were advised to the company on February 02, 2005.
Outlook, Risks, and Management Commentary
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—hold an interest in the shares held by the GSK Trust in the same manner as other employees. No specific guidance, risks, or unusual items regarding future operations are disclosed in this text.
Investor Verification Points
- Verify the total number of shares transferred from the GSK Trust on February 01, 2005 (28,470 total).
- Confirm the specific incentive plans receiving the share transfers.
- Review the full 20-F annual report for comprehensive financial metrics, as this 6-K filing contains only director interest disclosures.